A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

Prior treatment

• Have been treated with insulin within two weeks prior to screening

Other illness

• Have Type 1 Diabetes or gestational diabetes
• Have a history of chronic or acute pancreatitis
• Have acute or chronic hepatitis
• Have a history of an active or untreated malignancy
• Have New York Heart Association Functional Classification IV congestive heart failure

Other

• Have evidence of a significant, uncontrolled endocrine abnormality

• Have a clinical diagnosis of uncontrolled Type 2 Diabetes based on the World Health Organization classification or other locally applicable diagnostic standards, and who intend to fast during Ramadan
• Have HbA1c ≥7% within 30 days prior to screening
• Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve
• Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening
• Have body mass index ≥25 kilograms per square meter (kg/m2) at screening